These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 29171761)
1. New agents for the management of resistant metastatic breast cancer. Anampa J; Sparano JA Expert Opin Pharmacother; 2017 Dec; 18(17):1815-1831. PubMed ID: 29171761 [TBL] [Abstract][Full Text] [Related]
2. Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting. Dawood S; Konstantinova M; Perazzo F; Kim SB; Villarreal-Garza C; Franco SX; Simon SD; El-Nahas T Chin Clin Oncol; 2020 Oct; 9(5):61. PubMed ID: 32819114 [TBL] [Abstract][Full Text] [Related]
3. Advances in PARP inhibitors for the treatment of breast cancer. Dizdar O; Arslan C; Altundag K Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111 [TBL] [Abstract][Full Text] [Related]
4. Landmark trials in the medical oncology management of metastatic breast cancer. Lu P; Santa-Maria CA; Ballinger TJ; Sheng JY Semin Oncol; 2021 Jun; 48(3):246-258. PubMed ID: 34364700 [TBL] [Abstract][Full Text] [Related]
5. Can patients with metastatic breast cancer be cured after introduction of newer and more effective agents? Ohno S; Tanaka K; Koga C; Nishimura S; Yamaguchi H; Kawaguchi H; Yoshiyama T; Nakamura Y Breast Cancer; 2012 Jul; 19(3):212-7. PubMed ID: 21630056 [TBL] [Abstract][Full Text] [Related]
6. Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer. Sulai NH; Tan AR Clin Adv Hematol Oncol; 2018 Jul; 16(7):491-501. PubMed ID: 30067621 [TBL] [Abstract][Full Text] [Related]
7. Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer. Le D; Gelmon KA Expert Rev Clin Pharmacol; 2018 Sep; 11(9):833-839. PubMed ID: 30118334 [TBL] [Abstract][Full Text] [Related]
8. Recent developments in treatment stratification for metastatic breast cancer. Barton S; Swanton C Drugs; 2011 Nov; 71(16):2099-113. PubMed ID: 22035512 [TBL] [Abstract][Full Text] [Related]
9. Olaparib for the treatment of breast cancer. Robert M; Frenel JS; Gourmelon C; Patsouris A; Augereau P; Campone M Expert Opin Investig Drugs; 2017 Jun; 26(6):751-759. PubMed ID: 28395540 [TBL] [Abstract][Full Text] [Related]
10. Treating metastatic breast cancer with systemic chemotherapies: current trends and future perspectives. Smith NZ Clin J Oncol Nurs; 2012 Apr; 16(2):E33-43. PubMed ID: 22459535 [TBL] [Abstract][Full Text] [Related]
11. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer. Okuma HS; Yonemori K Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic innovations in breast cancer. Le Du F; Perrin C; Brunot A; Crouzet L; De La Motte Rouge T; Lefeuvre-Plesse C; Dieras V Presse Med; 2019 Oct; 48(10):1131-1137. PubMed ID: 31151842 [TBL] [Abstract][Full Text] [Related]
13. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy]. Schreiber V; Illuzzi G; Héberlé E; Dantzer F Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693 [TBL] [Abstract][Full Text] [Related]
14. The curability of breast cancer and the treatment of advanced disease. Guarneri V; Conte PF Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948 [TBL] [Abstract][Full Text] [Related]
15. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer. Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250 [TBL] [Abstract][Full Text] [Related]
16. [Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer]. Ma F; Xu BH; Li HH; Li Q; Zhang P; Yuan P; Wang JY; Fan Y; Li Q Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):521-4. PubMed ID: 24257305 [TBL] [Abstract][Full Text] [Related]
17. Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy. Geerinckx B; Teuwen LA; Foo T; Vandamme T; Smith A; Peeters M; Price T Expert Rev Anticancer Ther; 2023; 23(12):1237-1249. PubMed ID: 37842857 [TBL] [Abstract][Full Text] [Related]
18. Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities. Conlin AK; Seidman AD Clin Breast Cancer; 2008 Jun; 8(3):215-23. PubMed ID: 18650151 [TBL] [Abstract][Full Text] [Related]
19. Emerging therapeutic modalities of PARP inhibitors in breast cancer. Wang X; Shi Y; Huang D; Guan X Cancer Treat Rev; 2018 Jul; 68():62-68. PubMed ID: 29870916 [TBL] [Abstract][Full Text] [Related]
20. [PARP inhibitors and their role in the therapy of triple-negative metastatic breast cancer]. Kozioł M; Püsküllüoglu M; Zygulska A Przegl Lek; 2012; 69(6):265-70. PubMed ID: 23094440 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]